RxDoctor Payments Data

Perrin Downing, MD

Urogynecology and Reconstructive Pelvic Surgery · Allentown, PANPI 1306374376

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 33.5% of the total. 2025 is the largest year on record at $3,887, more than ten times the $224 reported in 2019.

$9,465in general payments, 2019–2025

Across 147 payments — averaging $64.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Coloplast$3K
  • Intuitive Surgical$1K
  • Boston Scientific$824
  • AbbVie$611
  • Astellas Pharma US Inc$574
  • plus $587 from 11 others

What the payments were for

  • Travel & lodging$3,59538%
  • Food & beverage$4,67249%
  • Education$1,19813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,465 in reported general payments places this provider in the 75th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$43,244
Medicare patients
109
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron40$22,079
MyrbetriqMirabegron11$6,784
Estradiol68$4,509
Solifenacin Succinate13$564
Methenamine Hippurate15$309
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$222
Clobetasol Propionate11$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$113$22,07940 claims
Astellas Pharma US IncMyrbetriq$574$6,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

Other urogynecology and reconstructive pelvic surgery in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →